Levodopa–carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry. (February 2019)

• Record Type: Journal Article
• Authors: Poewe, Werner; Chaudhuri, K Ray; Bergmann, Lars; Antonini, Angelo
• Is Part Of: Neurodegenerative disease management. Volume 9:Number 1(2019)
• Page Start: 39
• Page End: 46
• Publication Date: 2019-02
• Subjects: dyskinesia -- levodopa -- Parkinson's disease -- quality of life; Nervous system -- Degeneration -- Periodicals; 616.8
• DOI: 10.2217/nmt-2018-0034
• Languages: English
• ISSNs: 1758-2024

Abstract

Aim: To evaluate long-term effects of levodopa–carbidopa intestinal gel on dyskinesia burden.Patients & methods: Posthoc analysis of the GLORIA registry assessed subgroups of advanced Parkinson's disease patients with <4 and ≥4 h/day of levodopa-induced dyskinesia at baseline.Results & conclusions: Mean dyskinesia duration significantly (p < 0.0001) decreased by 3.5 h in patients with ≥4 h baseline dyskinesia; conversely, dyskinesia duration increased by 1.6 h in patients with <4 h baseline dyskinesia. Quality of life improved in both subgroups. Adverse drug reactions occurred at similar rates in both subgroups. Despite increases in levodopa dose, levodopa–carbidopa intestinal gel treatment led to significant and sustained reductions in dyskinesia time, severity and associated pain in advanced Parkinson's disease patients with high baseline dyskinesia burden.